Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori, discusses phase II results on progression-free survival for patients with advanced melanoma in the SECOMBIT study, whose aim is to evaluate the different sequencing of a BRAF inhibitor (encorafenib) plus a MEK inhibitor (binimetinib) with ipilimumab plus nivolumab (Abstract LBA45).
David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on sotorasib, a novel, first-in-class, oral KRASG12C inhibitor. The agent de...
Andreas Schneeweiss, MD, of the Heidelberg University Hospital and German Cancer Research Center, discusses phase III survival data from the GeparOcto trial, which compared t...
Monika K. Krzyzanowska, MD, MPH, of the Princess Margaret University Health Network, discusses study findings on remote proactive telephone-based toxicity management for patients w...
Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute, discusses an initial analysis of phase III findings from the PALLAS trial, which suggested the benefits observed in ...
Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Centre, discusses results of the phase II PRINCEPS trial, which assessed, for the first time, the effect of just one inj...
